Trials / Withdrawn
WithdrawnNCT02585479
Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
Systemic Chemotherapy VersusTranscatheter Arterial Chemoembolization As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Guangxi Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine that systemic chemotherapy is superior to transcatheter arterial chemoembolization in prolonging progression-free survival（PFS） in patients with Advanced Hepatocellular Carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pirarubicin | 1. Pirarubicin 30mg/m2 intravenously 2. Pirarubicin17mg/m2 are infused through the right and left hepatic arteries |
| DRUG | Oxaliplatin | 1. Oxaliplatin 100 mg/m2 intravenously 2. Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries |
| DRUG | Lipiodol | Lipiodol 5-10ml infused through the right and left hepatic arteries |
| DEVICE | Gelfoam | Hepatic artery embolization with Gelfoam. |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2017-10-01
- Completion
- 2017-10-01
- First posted
- 2015-10-23
- Last updated
- 2019-06-04
Source: ClinicalTrials.gov record NCT02585479. Inclusion in this directory is not an endorsement.